89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine

<p>– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin’s favorable safety and tolerability profile – – SHTG Phase 3 ENTRUST trial initiated in May 2023 – SAN FRANCISCO, June 24, 2023 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/89bio-publishes-positive-results-from-phase-2-entrigue-trial-of-pegozafermin-in-patients-with-severe-hypertriglyceridemia-shtg-in-nature-medicine/">89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>